Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Express Scripts
Moodys
AstraZeneca
Boehringer Ingelheim

Last Updated: August 8, 2022

Investigational Drug Information for Sotagliflozin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Sotagliflozin?

Sotagliflozin is an investigational drug.

There have been 37 clinical trials for Sotagliflozin. The most recent clinical trial was a Phase 3 trial, which was initiated on August 8th 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type 1. The leading clinical trial sponsors are Sanofi, Lexicon Pharmaceuticals, and Juvenile Diabetes Research Foundation.

There are thirty-four US patents protecting this investigational drug and three hundred and ninety-nine international patents.

Recent Clinical Trials for Sotagliflozin
TitleSponsorPhase
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceUniversity of GlasgowPhase 3
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceNHS Greater Glasgow and ClydePhase 3
Dapagliflozin Plus Pioglitazone in T1DMThe University of Texas Health Science Center at San AntonioPhase 4

See all Sotagliflozin clinical trials

Clinical Trial Summary for Sotagliflozin

Top disease conditions for Sotagliflozin
Top clinical trial sponsors for Sotagliflozin

See all Sotagliflozin clinical trials

US Patents for Sotagliflozin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sotagliflozin See Plans and Pricing Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
Sotagliflozin See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Sotagliflozin See Plans and Pricing Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sotagliflozin

Drugname Country Document Number Estimated Expiration Related US Patent
Sotagliflozin Australia AU2016209623 2035-01-20 See Plans and Pricing
Sotagliflozin Brazil BR112017015431 2035-01-20 See Plans and Pricing
Sotagliflozin Canada CA2973202 2035-01-20 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Express Scripts
Moodys
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.